$IMUX
Immunic Inc

2018 Q4 Form 10-Q Financial Statement

#000128077618000104 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.530M $2.460M $2.950M
YoY Change -44.88% -16.61% 6.5%
% of Gross Profit
Research & Development $150.0K $1.410M $9.689M
YoY Change -98.53% -85.45% 29.72%
% of Gross Profit
Depreciation & Amortization $100.0K $204.0K $216.0K
YoY Change -54.55% -5.56% -48.57%
% of Gross Profit
Operating Expenses $5.234M $1.805M $12.64M
YoY Change -64.59% -85.72% 23.44%
Operating Profit -$1.805M -$12.64M
YoY Change -85.72% 23.44%
Interest Expense $80.00K $110.0K $190.0K
YoY Change -60.0% -42.11% 137.5%
% of Operating Profit
Other Income/Expense, Net $10.00K $8.000K $158.0K
YoY Change -200.0% -94.94% 159.02%
Pretax Income -$2.460M -$11.94M -$12.48M
YoY Change -83.14% -4.33% 22.59%
Income Tax
% Of Pretax Income
Net Earnings -$4.812M -$1.797M -$12.48M
YoY Change -67.01% -85.6% 22.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.321M -$11.26M -$11.77M
COMMON SHARES
Basic Shares Outstanding 42.37M shares 42.37M shares 42.21M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.30M $17.80M $66.40M
YoY Change -76.63% -73.19% -2.5%
Cash & Equivalents $13.07M $17.80M $66.39M
Short-Term Investments
Other Short-Term Assets $68.00K $1.300M $1.600M
YoY Change -94.33% -18.75% 14.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.33M $19.06M $67.96M
YoY Change -77.06% -71.95% -2.17%
LONG-TERM ASSETS
Property, Plant & Equipment $40.00K $890.0K $2.272M
YoY Change -98.14% -60.83% -22.25%
Goodwill $0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $37.00K $126.0K
YoY Change -100.0% -70.63% 44.83%
Total Long-Term Assets $40.00K $927.0K $2.398M
YoY Change -98.23% -61.34% -20.31%
TOTAL ASSETS
Total Short-Term Assets $13.33M $19.06M $67.96M
Total Long-Term Assets $40.00K $927.0K $2.398M
Total Assets $13.37M $19.99M $70.36M
YoY Change -77.86% -71.59% -2.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $1.131M $981.0K
YoY Change 33.46% 15.29% -17.77%
Accrued Expenses $416.0K $4.552M $7.167M
YoY Change -95.45% -36.49% 113.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.920M $5.691M $8.234M
YoY Change -81.32% -30.88% 77.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $45.00K $46.00K
YoY Change -100.0% -2.17% -44.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.920M $5.691M $8.234M
Total Long-Term Liabilities $0.00 $45.00K $46.00K
Total Liabilities $1.920M $5.736M $8.280M
YoY Change -81.43% -30.72% 75.68%
SHAREHOLDERS EQUITY
Retained Earnings -$25.00M -$335.0M -$281.4M
YoY Change -91.55% 19.05% 21.23%
Common Stock $0.00 $4.000K $4.000K
YoY Change -100.0% 0.0% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$25.74M -$20.80M $62.08M
YoY Change
Total Liabilities & Shareholders Equity $13.37M $19.99M $70.36M
YoY Change -77.86% -71.59% -2.92%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$4.812M -$1.797M -$12.48M
YoY Change -67.01% -85.6% 22.63%
Depreciation, Depletion And Amortization $100.0K $204.0K $216.0K
YoY Change -54.55% -5.56% -48.57%
Cash From Operating Activities -$4.660M -$13.08M -$9.420M
YoY Change -53.02% 38.85% 19.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$270.0K -$160.0K
YoY Change -100.0% 68.75% -40.74%
Acquisitions
YoY Change
Other Investing Activities $180.0K $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $180.0K -$270.0K -$170.0K
YoY Change -263.64% 58.82% 240.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 20.00K -180.0K
YoY Change -100.0% -111.11% -107.41%
NET CHANGE
Cash From Operating Activities -4.660M -13.08M -9.420M
Cash From Investing Activities 180.0K -270.0K -170.0K
Cash From Financing Activities 0.000 20.00K -180.0K
Net Change In Cash -4.480M -13.33M -9.770M
YoY Change -52.79% 36.44% 77.31%
FREE CASH FLOW
Cash From Operating Activities -$4.660M -$13.08M -$9.420M
Capital Expenditures $0.00 -$270.0K -$160.0K
Free Cash Flow -$4.660M -$12.81M -$9.260M
YoY Change -52.45% 38.34% 21.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42369694 shares
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
dei Entity Small Business
EntitySmallBusiness
true
dei Trading Symbol
TradingSymbol
VTL
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1049000 USD
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1131000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9141000 USD
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4552000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10323000 USD
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10947000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
78000 USD
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
345915000 USD
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
349132000 USD
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-119000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-357000 USD
CY2017Q4 us-gaap Assets
Assets
60384000 USD
CY2018Q3 us-gaap Assets
Assets
19988000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
58121000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
780000 USD
us-gaap Severance Costs1
SeveranceCosts1
2395000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3643000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3097000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11941000 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
19061000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59991000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39009000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66391000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56901000 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17798000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6400000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-39103000 USD
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
92.99
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9498272 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42368864 shares
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42369694 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42368864 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42369694 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12483000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37485000 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
91000 USD
CY2018Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
8000 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
59000 USD
CY2018Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
45000 USD
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
216000 USD
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
204000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
628000 USD
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3591000 USD
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1081000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2950000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8724000 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2461000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11054000 USD
CY2017Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2018Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1219000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1219000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1200000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
211000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
94000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2512000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4583000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-11000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-98000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
125000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
191000 USD
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
187000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
453000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-567000 USD
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
114000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
445000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
115000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60384000 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19988000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10281000 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5691000 USD
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
59000 USD
CY2018Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
45000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37444000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-595000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30477000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38512000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-12481000 USD
us-gaap Net Income Loss
NetIncomeLoss
-37490000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-11941000 USD
us-gaap Net Income Loss
NetIncomeLoss
-39011000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
158000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
385000 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
123000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
462000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
12639000 USD
us-gaap Operating Expenses
OperatingExpenses
37875000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
12064000 USD
us-gaap Operating Expenses
OperatingExpenses
39473000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12639000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-37875000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12064000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-39473000 USD
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
253000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
736000 USD
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
270000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
844000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173000 USD
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
182000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
108000 USD
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
37000 USD
CY2017Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4000 USD
CY2018Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2000 USD
CY2017Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
597000 USD
CY2018Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
91000 USD
CY2018Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-68000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
3000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
218000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
86000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
574000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1220000 USD
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1263000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37500000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37529000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
7000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
2000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12478000 USD
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11837000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2155000 USD
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
890000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9689000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29151000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5989000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24805000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295953000 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-334964000 USD
CY2017Q3 us-gaap Severance Costs1
SeveranceCosts1
0 USD
us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2018Q3 us-gaap Severance Costs1
SeveranceCosts1
2395000 USD
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4473207 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
1444286 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2815900 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.18
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6083482 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7454266 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.76
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.77
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6744346 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.87
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.35
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
830 shares
CY2017Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40300000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
50044000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
14252000 USD
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42207376 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39054978 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42369437 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42369093 shares
CY2017Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
5377000 USD
CY2018Q3 vtl Accrued Clinical Costs
AccruedClinicalCosts
3289000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
10000 USD
vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
0 USD
CY2018Q3 vtl Entity Public Float Maximum Amount Equity Issuance Under The Shelf Registration Agreement Would Be Limited
EntityPublicFloatMaximumAmountEquityIssuanceUnderTheShelfRegistrationAgreementWouldBeLimited
75000000 USD
CY2018Q2 vtl Entity Public Float Maximum Amount Equity Issuance Under The Shelf Registration Agreement Would Be Limited
EntityPublicFloatMaximumAmountEquityIssuanceUnderTheShelfRegistrationAgreementWouldBeLimited
75000000 USD
CY2018Q3 vtl Issuance Of Securities Authorized Offering Amount Under Shelf Registration
IssuanceOfSecuritiesAuthorizedOfferingAmountUnderShelfRegistration
200000000 USD
CY2018Q2 vtl Maximum Aggregate Offering Priceof Securities Under Shelf Registration
MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
200000000 USD
CY2018Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
60000000 USD
CY2018Q2 vtl Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders
MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders
2500000 shares
CY2018Q3 vtl Reduction In Accrued Clinical Costs Due To Change In Estimate
ReductionInAccruedClinicalCostsDueToChangeInEstimate
356000 USD
CY2018Q3 vtl Reduction In Research And Development Expense Due To Change In Estimate
ReductionInResearchAndDevelopmentExpenseDueToChangeInEstimate
356000 USD
vtl Reduction In Research And Development Expense Due To Change In Estimate
ReductionInResearchAndDevelopmentExpenseDueToChangeInEstimate
356000 USD
CY2018Q3 vtl Reversal Of Allocated Share Based Compensation Expense Due To Change In Estimate
ReversalOfAllocatedShareBasedCompensationExpenseDueToChangeInEstimate
1700000 USD
vtl Reversal Of Allocated Share Based Compensation Expense Due To Change In Estimate
ReversalOfAllocatedShareBasedCompensationExpenseDueToChangeInEstimate
-1700000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-18-000104-index-headers.html Edgar Link pending
0001280776-18-000104-index.html Edgar Link pending
0001280776-18-000104.txt Edgar Link pending
0001280776-18-000104-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-093018xexhibit311.htm Edgar Link pending
vtl-093018xexhibit312.htm Edgar Link pending
vtl-093018xexhibit321.htm Edgar Link pending
vtl-093018xexhibit322.htm Edgar Link pending
vtl-20180930.xml Edgar Link completed
vtl-20180930.xsd Edgar Link pending
vtl-20180930_cal.xml Edgar Link unprocessable
vtl-20180930_def.xml Edgar Link unprocessable
vtl-20180930_lab.xml Edgar Link unprocessable
vtl-20180930_pre.xml Edgar Link unprocessable
vtl-93018x10q.htm Edgar Link pending